title: [Intra-arterial infusion chemotherapy with epirubicin for advanced breast cancer].
abstract: Thirty-two patients with locally advanced or disseminated breast cancer were treated with preoperative intra-arterial infusion chemotherapy with epirubicin (30 mg/m2, day 1, 4, 7). The results were as follows: 1) the response rate (CR + PR) was as high as 71.9% (23/32) in the primary lesions. Marked degenerative changes were, also, histologically observed in 22 cases (68.8%). 2) As for side effects, mild grade of leukopenia and hair loss were frequently encountered in 75.0% and 62.5%, respectively. Gastrointestinal disorders, however, was extremely rare (6.3%). 3) Follow-up time was not long enough, but considerable survival advantages were suggested. The author confirmed that intra-arterial infusion chemotherapy with epirubicin was an efficacious modality for the treatment of advanced breast cancer.
authors.affiliation: Dept. of Surgery, Osaka National Hospital.
authors.forename: Y
authors.initials: Y
authors.lastname: Takatsuka
authors.forename: T
authors.initials: T
authors.lastname: Kawahara
authors.forename: E
authors.initials: E
authors.lastname: Yayoi
authors.forename: J
authors.initials: J
authors.lastname: Okamura
authors.forename: K
authors.initials: K
authors.lastname: Miyauchi
authors.forename: T
authors.initials: T
authors.lastname: Mori
mesh_terms: D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D004341:Drug Evaluation; D015251:Epirubicin / Q000008:administration & dosage* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007261:Infusions, Intra-Arterial; D008875:Middle Aged; D012074:Remission Induction; D015996:Survival Rate
chemical_list: D015251:Epirubicin